Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 10th International Conference on Liver Diseases & Hepatology | Tokyo, Japan.

Day 1 :

Liver Diseases 2019 International Conference Keynote Speaker Prof.Antonio Iannetti photo

Degree in Medicine and Surgery and Specialties in "Gastroenterology" and "Internal Medicine" at the University of Rome.1980-1983 University of Los Angeles (USA), he is interested endoscopic sclerosis of esophageal varices and retrograde cholangiopancreatography-endoscopically. University Professor - Chair of Gastroenterology - University of Rome. Head of the Digestive Endoscopy Service of the University Hospital Umberto I in Rome. Professor of "Endoscopy" and "Digestive System Diseases" at the Faculty of Medicine, University of Rome - "La Sapienza."Lecturer in E.C.M. Courses (Continuing Medical Education), national and international. Expert of the Ministry of Health for Gastroenterology


Digestive endoscopy is a recent branch of Medicine, which joins Gastroenterology.In Europe, it has never become a separate discipline.Endoscopy was initially associated with Surgery, especially in Italy, but subsequently, as per European provisions, this branch is now an integral part of Gastroenterology. We Gastroenterology Teachers meet at least twice a year, at conferences organized by UNIGASTRO, which is the association of university professors of Gastroenterology in Italy. Above all, at the level of Specialization Schools, we set ourselves the problem of dividing the discipline of Gastroenterology into two subtypes: Hepatological Gastroenterology and Endoscopic Gastroenterology. This has never happened, for reasons of political opportunity, neither in Italy nor in Europe. However, it is clear that the Specialist in Gastroenterology must make a choice. Digestive Endoscopy increasingly takes on an autonomous role, considering all the diagnostic and therapeutic procedures that can be performed. I just want to make a quick reference to diagnostic and interventional echo-endoscopy, with ultrasound-guided biopsies, needle aspiration and pancreatic cyst drainage. Then, there are endoscopic fundoplication interventions for reflux disease, such as the GERDX and the MUSE methods, and the Per-Oral Endoscopic Myotomy (POEM), for the treatment of achalasia. In my report at the Gastroenterology and Hepatology Congress in December 2019 in Tokyo, I will talk about how Digestive Endoscopy has made and is making huge strides in the autonomous diagnosis of superficial neoplastic lesions, known as intestinal polyps. This aspect is very important, in order to be able to decide, on the spot, from the Operator, if and how to intervene on the lesion, in which one comes across. Being able to have validated classifications, on the basis of which it is possible to know what type of neoplastic lesion we are facing and how much it invades the surrounding tissues, gives us the possibility of deciding whether to resect it immediately or not and how to resect it. In this important choice, the endoscopic instruments at our disposal and their advanced features, such as magnification, electronic staining and laser confocal endomicroscopy have a fundamental role.

Liver Diseases 2019 International Conference Keynote Speaker Dr Iftikhar Ahmed photo

Dr Ahmed is a consultant gastroenterologist at Aldar Hospital and Medical Centre Riyadh KSA and visiting consultant at East Sussex Hospitals NHS foundation trust Eastbourne. He is also an Adjunct Associate Professor at Alfaisal University Riyadh, and an Hon. Senior clinical lecturer at the University of Southampton UK. His research interests include investigating the changes in the smell of faeces and breathe in order to understand the pathophysiological mechanisms of GI disorders and to develop a non-invasive biomarker. Through formal laboratory research, Dr Ahmed studied the faecal volatile metabolomics profiles of patients with Liver disease, inflammatory bowel disease and irritable bowel syndrome (IBS) in comparison with healthy individuals, and was awarded the degree of Doctorate of Medicine (MD) by University of the Bristol in 2012. Dr Ahmed has collaborative research experience with international colleagues, presented his work at both national and international conferences, and was awarded travel grants and prizes for the best abstracts and oral presentations on various occasions.
Dr Ahmed is on the reviewer panel of several national and international journals, including Gut, PLoS One, Journal of Gastrointestinal and Liver Disease and BMJ.


The diagnosis of liver disorders often requires extensive and invasive investigations including liver biopsy, and places a heavy burden both on healthcare resources and on the individuals during the period of disease-related disability leading to poor quality of life. Recently, there has been increasing scientific interest in the non-invasive biomarkers to diagnose liver diseases and to monitor the disease activity. Volatile organic metabolites have emerged as innovative biomarkers on the diagnostic armamentarium of GI and Liver diseases in the current era. The development of sophisticated analytical techniques has enabled the study and interpretation of changes in the faecal and breath volatile organic metabolites (VOMs) and its correlation with the pathophysiological mechanisms in liver disorders. VOMs are the chemicals that are the products and
intermediates of metabolism and may be altered during the diseases process. Changes in the signature of VOMs could potentially provide diagnostic information about health and disease. Multiple studies have reported the differences in VOM profiles of healthy controls compared to patients with liver disease. VOM profiles have been used to segregate patients by disease activity and the type of disease. The correlation of VOMs with microbiota is interesting and supports the hypothesis of gut microbial dysbiosis in the etiology of liver disease. This also provides an important platform to explore the role of dysbiosis in the pathogenesis of liver diseases and other GI disorders leading to the discovery of novel therapeutic targets. In future, further understanding of faecal VOMs may lead to the development of a rapid and simple point of care diagnosis and monitoring of liver disorders.

Liver Diseases 2019 International Conference Keynote Speaker Prof. Higinio Mappala photo

Professor Higinio T. Mappala is a Full-time Medical Specialist IV and Administrator at the Jose Reyes Memorial Medical Center, Manila, Philippines, A Board-certified Internist, Gastroenterologist, Endoscopist, Clinical Nutritionist and Clinical Toxicologist; has served as a University Professor and Dean of 2 Medical Schools; a highly-regarded Researcher, with more than 70 scientific papers, and more than 30 international publications. A former Board Director of the Philippine Societies of Gastroenterology and Digestive Endoscopy; Editorial Board member, American Journal of Biomedical Science and Reearch; Online Research rater of McMaster, Canada and Online Dynamed Research peer-reviewer; a Young Investigator’s Awardee at the World Congress and Asia-Pacific Congress of Gastroenterology; A nominee as one of the Top 100 Leading Physicians 2018, Cambridge Biographical Institute. He is a focused lecturer on NAFLD in local and international conventions, with 18 invites as Keynote Speaker in 2018 and 35 invites in 2019


Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-alcoholic steatohepatitis (NASH). Currently there are no therapeutic strategies for such disease. Only lifestyle modification through diet and exercise were proven to afford some benefit in patients with NAFLD. No pharmacologic agents have so far been approved for the treatment of NAFLD or NASH. Therefore, most clinical efforts have been directed at treating the components of metabolic syndrome, namely obesity, diabetes, hypertension and dyslipidemias. Other interventions are directed at specific pathways potentially involved in the pathogenesis of NAFLD, such as insulin resistance, oxidative stress, pro-inflammatory cytokines, apoptosis, bacterial overgrowth, and angiotensin pathway. However, since the FLINT study, the largest NASH study to date, no drug has ever come close to Obeticholic acid except Ursodeoxycholic acid (UDCA). This lecture aims to show the potential of Ursodeoxycholic Acid (UDCA) as a promising therapeutic option for NAFLD. This is a 10-year Systematic Review of randomized controlled trials on the effects of Ursodeoxycholic Acid on Non-Alcoholic Fatty Liver Disease. (NAFLD). Ursodeoxycholic Acid may yet prove to be a targeted treatment for Non-Alcoholic Fatty Liver Disease.